Introduction
============

Squamous cell carcinoma (SCC) is the most common malignant tumor of the oral cavity and head and neck. Oral SCC involves lymphatic metastasis, but not blood-borne metastasis, and it metastasizes to the regional lymph nodes in 30--40% of cases. Patient prognosis depends on the presence of lymph node metastasis. However, little is known about the molecular mechanisms underlying lymph node metastasis in SCC of the oral cavity. We have previously reported the relationship between lymphangiogenesis and the expression of VEGF-C and VEGF-D in association with lymph node metastasis in oral SCC.

Epithelial-mesenchymal transition (EMT) refers to a series of events that results in conversion of epithelial cells which adhere each other to individual migratory cells that can invade into extracellular matrix ([@b1-ijo-41-06-1985]). EMT is crucial for appropriate development in the early embryo, and this process also plays an important role in adults during wound healing, tissue regeneration, and cancer progression ([@b2-ijo-41-06-1985]). It is closely related to poor prognosis of various types of cancer \[gastric ([@b3-ijo-41-06-1985]), colon ([@b4-ijo-41-06-1985]), breast ([@b5-ijo-41-06-1985],[@b6-ijo-41-06-1985]), esophageal ([@b7-ijo-41-06-1985]), lung ([@b8-ijo-41-06-1985]), and ovarian ([@b9-ijo-41-06-1985])\]. In oral cancer, EMT in tongue squamous cell carcinoma (SCC) has been reported to be related to tumor satellite formation ([@b10-ijo-41-06-1985]) and lymph node metastasis ([@b11-ijo-41-06-1985]). These reports suggest that EMT is a precursor of SCC metastasis and that it induces tumor cell dissemination from the primary tumor site.

The EMT events during tumor progression are controlled by genes that are normally expressed in the early embryo (e.g., *Twist, Snail, Slug, Goosecoid* and *SIP1*) ([@b7-ijo-41-06-1985],[@b12-ijo-41-06-1985]--[@b15-ijo-41-06-1985]). The transcription factors encoded by these genes can induce characteristics of mesenchymal cells, such as cell motility and invasiveness, in tumor cells. For example, the expression of Twist is increased in various types of malignant tumors, including breast cancer, prostate cancer, gastric cancer, and melanoma ([@b16-ijo-41-06-1985],[@b17-ijo-41-06-1985]).

Recently, the T-box transcription factor Brachyury, a gene required for mesoderm formation during early development ([@b18-ijo-41-06-1985],[@b19-ijo-41-06-1985]), was reported to promote EMT in human carcinoma cell lines ([@b20-ijo-41-06-1985]). This study also showed that ectopic overexpression of Brachyury by gene transfection in human carcinoma cells induced characteristic changes of EMT. Based on these findings, it is proposed that EMT in cancer cells is controlled by mechanisms similar to EMT in human developmental processes.

In this study, we investigated the patterns and levels of expression of T-box transcription factor Brachyury, using immunohistochemistry on oral SCC specimens, and analyzed the relationship between Brachyury expression and EMT. We also statistically analyzed the correlation between Brachyury expression and prognosis, focusing on lymph node metastasis.

Patients and methods
====================

Patients and tumor specimens
----------------------------

This study was based on a retrospective cohort of 152 patients who had been diagnosed with primary oral SCC and treated at the Department of Oral and Maxillofacial Surgery, Kyushu University Hospital, Fukuoka, Japan, between 1993 and 2006. All biopsies were obtained from the patients before any treatment was administered. The clinicopathological information associated with each case, including age, gender, tumor size, nodal status, location, treatment, and the presence or absence of recurrence and metastasis, was obtained from patient files. Ninety-seven men and 55 women were involved; median age was 61 years, range 24--85. All patients were staged according to the UICC TNM Classification of Malignant Tumors ([@b21-ijo-41-06-1985]). When cervical metastasis was clinically equivocal, neck dissection was performed, and the metastases were diagnosed histologically. The protocol for the research project was approved by the appropriate Ethics Committee of Kyushu University.

Immunohistochemistry
--------------------

Biopsy samples were fixed in 10% neutralized buffered-formalin. Consecutive 4-*μ*m sections were cut and deparaffinized with xylene, rehydrated in a graded alcohol series, and heat treated with Target Retrieval Solution (Dako, Carpinteria, CA, USA) before histopathological and immunohistochemical analysis. The grade of tumor differentiation was determined using the criteria proposed by the World Health Organization ([@b22-ijo-41-06-1985]). The histological mode of invasion was classified according to the Anneroth classification ([@b23-ijo-41-06-1985]).

To block endogenous peroxide activity, 3% H~2~O~2~ was applied, and non-specific antibody binding was blocked with 10% normal serum in Tris-HCl buffer. The sections were incubated overnight at 4°C with the following primary antibodies: rabbit polyclonal antibody against human Brachyury (H-210, Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal antibody against human E-cadherin (610181, BD Bioscience, San Jose, CA, USA); and goat polyclonal antibody against human Vimentin (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunostaining was performed with the Histofine SAB-PO kit (Nichirei, Tokyo, Japan), according to the manufacturer's instructions. The immunolocalization of the protein was visualized using a DAB substrate kit (Nichirei). Sections were counterstained with 0.5% hematoxylin, dehydrated, cleared, and mounted. Negative control staining involved substituting non-immune goat serum for the primary antibodies.

We evaluated the staining pattern of the indicated proteins at the invasive edge of the primary tumors for all the specimens. The density of staining for Brachyury and E-cadherin was evaluated by measuring the difference between the mean density (pixels) of 10 randomly selected positive-staining fields in SCC and the mean density of background staining, using the analyze tool in Photoshop CS5 Extended (Adobe Systems Inc., San Jose, CA, USA). To avoid any measurement errors derived from staining heterogeneity, we also measured the mean density of staining for each protein in normal cells (lymphocytes for Brachyury and normal epithelium for E-cadherin) as positive controls in the same sample, and the ratio of staining density between SCC and positive control was calculated. This ratio was taken to represent the expression level of the protein. For Vimentin, the number of the positive SCC cells in a low-power field was counted. The results were classified into 3 groups for each protein as shown in [Table I](#t1-ijo-41-06-1985){ref-type="table"}: ++, strong staining; +, moderate staining; and −, negative ([Figs. 1](#f1-ijo-41-06-1985){ref-type="fig"} and [2](#f2-ijo-41-06-1985){ref-type="fig"}). Two independent observers blinded to the patient status scored the samples.

Immunofluorescence staining
---------------------------

Sections were cut and mounted as described above and heat treated with Target Retrieval Solution (Dako) before immunofluorescence staining. Non-specific antibody binding was blocked with 3% BSA in phosphate-buffered saline (PBS) for 1 h at room temperature. The sections were incubated overnight at 4°C with primary antibodies as described above. Following three 10-min washes in PBS, sections were incubated with secondary antibodies for 1 h at room temperature. The secondary antibodies (Invitrogen, Carlsbad, CA, USA) used were: for Brachyury, Alexa Fluor 498 goat anti-mouse, catalog no. A11034; for E-cadherin, Alexa Fluor 350 goat anti-mouse, catalog no. A11029; for Vimentin, Alexa Fluor 594 donkey anti-goat, catalog no. A11058. After additional washes, images were captured using a Z-axis-controlled microscope with a CCD camera (BZ-8000; Keyence, Osaka, Japan) and processed for deconvoluted fluorescence imaging.

Statistical analysis
--------------------

Statistical analysis was performed with the statistical software package SPSS for Windows (Abacus Concepts, Berkeley, CA, USA). Relationships between staining intensity of markers and various clinicopathological factors were assessed with the χ^2^ test. To define independent risk factors for lymph node metastasis and distant metastasis, univariate and multivariate analysis were performed with a logistic regression analysis. The survival rate was estimated with the Kaplan-Meier method and analyzed using the log-rank test. Differences were considered significant at p\<0.05.

Results
=======

EMT pattern in oral SCC
-----------------------

We examined EMT in oral SCC lesions by assessing loss of E-cadherin and gain of Vimentin using immunohistochemistry. E-cadherin was localized on the cell membrane of SCC cells but was lost in some cases, whereas Vimentin was stained in the cytoplasm of SCC cells and in the stromal tissue ([Fig. 1](#f1-ijo-41-06-1985){ref-type="fig"}). We categorized E-cadherin and Vimentin staining by staining intensity and scored the staining patterns as EMT (E-cadherin-negative, Vimentin-positive) or not EMT.

[Table II](#t2-ijo-41-06-1985){ref-type="table"} summarizes clinicopathological data of all cases and E-cadherin and Vimentin immunoreactivity. The relationship between E-cadherin and Vimentin expression and clinicopathological factors was analyzed with the χ^2^ test. The staining intensity of E-cadherin on SCC cells was significantly associated with lymph node involvement (p= 0.049), distant metastasis (p= 0.001), and tumor differentiation (p= 0.041), while the intensity of Vimentin staining was associated with lymph node involvement (p= 0.009) and distant metastasis (p= 0.002). The relationship between EMT pattern and clinicopathological factors was also analyzed with the χ^2^ test. Lymph node involvement (p=0.009) and distant metastasis (p=0.001) were significantly correlated with presence of the EMT pattern.

Pattern and level of expression of Brachyury in oral SCC
--------------------------------------------------------

We next examined the expression of Brachyury in oral SCC lesions using immunohistochemistry. Brachyury protein was localized in the cytoplasm and/or the nucleus of SCC cells. Brachyury was occasionally detected in lymphocytes around the SCC nests and in stromal cells surrounding the SCC nests. SCC cells in the invasive front tended to be stained strongly ([Fig. 2](#f2-ijo-41-06-1985){ref-type="fig"}). We categorized Brachyury staining by staining intensity in the cytoplasm or nucleus and by pattern of cellular localization: Type I, negative staining; Type II, positive only in the cytoplasm; Type III, positive only in the nucleus; and Type IV, positive in both the cytoplasm and nucleus. The relationship between Brachyury expression (intensity and pattern) and clinicopathological factors was analyzed with the χ^2^ test ([Table III](#t3-ijo-41-06-1985){ref-type="table"}).

The rate of positive expression of Brachyury was 71.0% (Type I, 28.9%; Type II, 11.8%; Type III, 27.0%; and Type IV, 32.2%). Nuclear staining intensity of Brachyury in SCC cells was significantly associated with clinical T stage (p=0.001), lymph node involvement (p= 0.003), tumor differentiation (p=0.043), and the pattern of invasion (p=0.024), while cytoplasmic intensity of Brachyury was associated only with lymph node involvement (p=0.028) and the pattern of invasion (p=0.022).

The staining pattern of Brachyury on SCC cells was more significantly associated with clinicopathological factors than intensity of Brachyury; the pattern was associated with clinical T stage (p=0.001), lymph node involvement (p=0.004), tumor differentiation (p= 0.03), and the pattern of invasion (p= 0.006).

Molecular localization of Brachyury and EMT markers in oral SCC
---------------------------------------------------------------

To find direct evidence that Brachyury is associated with EMT, we analyzed localization of Brachyury, E-cadherin, and Vimentin in oral SCC tissues by triple immunofluorescence staining. [Fig. 3A](#f3-ijo-41-06-1985){ref-type="fig"} shows that Brachyury-negative cells strongly express E-cadherin. In contrast, stromal cells express Brachyury and Vimentin. [Fig. 3B](#f3-ijo-41-06-1985){ref-type="fig"} shows that SCC cells expressing both Brachyury and Vimentin were found at the invasive front of the primary nest.

Relationships between Brachyury expression and EMT in oral SCC
--------------------------------------------------------------

The relationship between Brachyury expression pattern and EMT (staining intensity of E-cadherin and Vimentin or scored pattern) was analyzed with the χ^2^ test ([Table IV](#t4-ijo-41-06-1985){ref-type="table"}).

Brachyury expression pattern was significantly correlated with Vimentin expression (p=0.002). In particular, Type IV staining was strongly associated with expression of Vimentin. Brachyury expression pattern was also significantly correlated with EMT (p=0.035).

Logistic regression analysis of the predictive factors for lymph node and distant metastasis
--------------------------------------------------------------------------------------------

To examine the significance of the predictive factors for lymph node metastasis, a logistic regression analysis was performed ([Table V](#t5-ijo-41-06-1985){ref-type="table"}). A univariate analysis showed that EMT, positive expression of Brachyury, and Vimentin, and negative expression of E-cadherin were related to lymph node metastasis (odds ratios 5.936, 4.39, 3.368, and 0.444, respectively), while EMT, lacking expression of E-cadherin, and Vimentin were related to distant metastasis (odds ratios 11.768, 0.113, and 4.558, respectively). Multivariate analysis also showed that positive expression of Brachyury was related to lymph node metastasis (odds ratio 3.952), while negative expression of E-cadherin was related to distant metastasis (odds ratio 0.141). Brachyury expression exhibited the highest odds ratios (4.390 and 3.952) among the predictive factors for lymph node metastasis, and E-cadherin exhibited the most significant odds ratios (0.113 and 0.141) among the predictive factors for distant metastasis.

Correlation between Brachyury expression and/or EMT and survival time
---------------------------------------------------------------------

To investigate whether Brachyury expression and/or EMT pattern in biopsy specimens predicts outcome in patients with oral SCC, Kaplan-Meier analysis for staining intensity of Brachyury, E-cadherin, and Vimentin of the overall ([Fig. 4A](#f4-ijo-41-06-1985){ref-type="fig"}) and disease-free ([Fig. 4B](#f4-ijo-41-06-1985){ref-type="fig"}) survival times was performed ([Fig. 4](#f4-ijo-41-06-1985){ref-type="fig"}). The 5-year overall survival rate of patients with Brachyury-positive SCC (80.6%) was significantly less than that of the negative counterpart (100%, log-rank test, p= 0.002; χ^2^, 9.477). The survival time of patients with E-cadherin-negative SCC (−) was significantly less than that of the weak (+) and strong (++) positive counterparts (log-rank test, p= 0.032; χ^2^ 4.607; p= 0.027; χ^2^, 4.888, respectively). The survival time of patients with strong Vimentin-positive (++) SCC was significantly less than that of the negative counterpart (log-rank test, p\<0.001; χ^2^, 15.684).

We also analyzed the survival time for EMT pattern or Brachyury expression with EMT pattern by the Kaplan-Meier method ([Fig. 5A](#f5-ijo-41-06-1985){ref-type="fig"}, overall survival rate; [Fig. 5B](#f5-ijo-41-06-1985){ref-type="fig"}, disease-free survival rate). The survival time of patients with SCC exhibiting the EMT pattern was strikingly shorter than in EMT-negative groups. The 5-year overall survival rate in these patients was 41.7% (log-rank test, p= 0.001; χ^2^, 31.196) and the 5-year disease-free survival rate was 25.0% (log-rank test, p\<0.001; χ^2^, 20.879). Moreover, survival time of patients with Brachyury expression and EMT pattern was significantly shorter than in Brachyury-negative groups; 5-year overall survival rate was 36.2% (log-rank test, p= 0.01; χ^2^, 38.319) and 5-year disease-free survival rate was 27.3% (log-rank test, p\<0.001; χ^2^, 27.837).

Discussion
==========

Cancer invasion and metastasis are crucial events in disease progression and largely determine prognosis of cancer patients. Many factors regulate cancer cell behavior, and correlation between clinical prognoses and expression of these factors in various tumors has led to their use as prognostic markers. Recently, EMT has been identified as not a factor but a crucial event in cancer invasion and metastasis during which many factors are simultaneously regulated ([@b24-ijo-41-06-1985],[@b25-ijo-41-06-1985]). In this regard, EMT patterns in tumor tissue are likely to be useful for estimating cancer prognosis.

We used loss of E-cadherin and gain of Vimentin as a marker of EMT, and we found a significant correlation between EMT pattern and lymph node involvement or distant metastasis ([Table II](#t2-ijo-41-06-1985){ref-type="table"}). Interestingly, Vimentin expression showed a stronger relationship with distant metastasis than did E-cadherin expression. Loss of E-cadherin is thought to be a hallmark of EMT, because loss of E-cadherin loosens cell-cell adhesion enabling cancer cells to escape from the primary cancer nest ([@b26-ijo-41-06-1985]). For example, in one recent study, the downregulation of E-cadherin shows significant difference compared to the pattern of invasion, tumor satellite formation, and tumor satellite size ([@b10-ijo-41-06-1985]). On the other hand, Vimentin overexpression in cancer tissues also correlates with tumor growth, tumor invasion, and poor clinical outcome ([@b3-ijo-41-06-1985],[@b27-ijo-41-06-1985]). In oral cancer, expression of Vimentin significantly increases in groups stratified by tumor satellite distance ([@b10-ijo-41-06-1985]). Vimentin overexpression induces tyrosine kinase expression and results in cancer cell migration ([@b28-ijo-41-06-1985]). This could explain the strong correlation between Vimentin expression and distant metastasis.

The mechanisms by which EMT is regulated in cancer cells are still not well understood. Recently, Fernando *et al*([@b20-ijo-41-06-1985]) reported that Brachyury, a gene required for mesoderm formation during early development, promotes EMT in human carcinoma cell lines. Their study showed that overexpression of Brachyury in human cancer cells induced characteristic changes of EMT, including elevated level of mesenchymal markers, decrease of epithelial markers, and increased cell migration and invasion. In our immunohistochemical analysis, Brachyury expressing cancer cells lost E-cadherin and gained Vimentin expression, consistent with previous reports and [Fig. 3](#f3-ijo-41-06-1985){ref-type="fig"}. Based on these data, we hypothesized that Brachyury expression is linked to EMT and correlated with disease prognosis. Therefore, we analyzed the relationship between Brachyury expression and clinicopathological findings ([Table III](#t3-ijo-41-06-1985){ref-type="table"}). Brachyury expression correlated with clinical T stage, lymph node involvement, tumor differentiation, and pattern of invasion. Importantly, cellular localization of Brachyury is more important factor than staining intensity. Brachyury is a T-box transcription factor that transduces cellular signals by translocation to the nucleus. Nuclear localization of Brachyury was significantly related to malignant phenotypes in oral cancer ([Table III](#t3-ijo-41-06-1985){ref-type="table"}). A role for Brachyury in promotion of EMT is supported by our finding that Brachyury cellular localization was significantly correlated with Vimentin expression and EMT pattern ([Table IV](#t4-ijo-41-06-1985){ref-type="table"}).

It is also noteworthy that EMT and Brachyury expression in oral SCC showed a significant correlation with lymph node involvement ([Table V](#t5-ijo-41-06-1985){ref-type="table"}). These findings suggest that Brachyury is one of the key elements in the control of EMT and that EMT is one of the most important events in the development of malignant phenotypes.

The existence of self-renewing, stem-like cells within tumors, called cancer stem cells (CSCs), has been proved. CSCs form a minor population in cancer cells within a tumor and are defined by their ability to establish new tumors. Hence, CSCs are also called 'tumor-initiating cells' ([@b29-ijo-41-06-1985]). During cancer cell metastasis, which is often enabled by EMT ([@b30-ijo-41-06-1985]), cancer cells which escape from primary site would require a self-renewal capability similar to that exhibited by stem cells in order to generate a new tumor in distant site. In this regard, the EMT process may also give a self-renewal capability to metastatic cancer cells. Indeed, emerging evidence of a direct interaction between EMT and CSCs has been reported ([@b20-ijo-41-06-1985],[@b31-ijo-41-06-1985],[@b32-ijo-41-06-1985]). Expression of SOX2, a member of the SOX (SRY-related high mobility group box) family, was recently shown to be significantly associated with poor prognosis in oral tongue SCC ([@b33-ijo-41-06-1985]). SOX2 was originally characterized as an important regulator of the maintenance of embryonic stem cell pluripotency ([@b34-ijo-41-06-1985]). It is possible that SOX2 can function to maintain CSCs.

Like SOX2, Brachyury is an important gene in embryonic development and induces EMT in early embryonic stages and in cancer cells ([@b35-ijo-41-06-1985]). These similarities raise the possibility that Brachyury is also an important regulator of CSC maintenance. Notably, recent clinical evidence suggests that Brachyury regulates CSCs in colorectal cancer ([@b36-ijo-41-06-1985]). The report suggests that Brachyury regulates Nanog in mesenchymal-like cancer cells to impose a plastic state, allowing competence of cells to respond to signals prompting invasion or metastasis. In preliminary work in our laboratory, Brachyury knockdown by short hairpin RNA in oral cancer stem cells completely inhibited the EMT phenotype and cancer stem cell phenotypes (tumorigenicity and sphere formation) *in vitro* (Sugiura, unpublished data). If Brachyury directly regulates CSCs, Brachyury expression could be a predictor of the effects of chemotherapy and radiotherapy, because CSCs were shown to be resistant to chemotherapy and radiotherapy *in vitro*([@b37-ijo-41-06-1985],[@b38-ijo-41-06-1985]). Furthermore, Brachyury could be a therapeutic target for anti-CSC therapy. Therefore, the effects of Brachyury in CSCs should be further investigated.

In conclusion, this study presents clinical evidence for an important role for Brachyury in EMT in oral SCC, and suggests that Brachyury expression and EMT patterns are useful prognostic markers.
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![Immunohistochemical analysis of E-cadherin and Vimentin expression in SCC tissue. For the histopathological and immunohistochemical analysis, 4-*μ*m-thick sections were used as described in Patients and methods. Staining intensity of E-cadherin and Vimentin in SCC cells was classified as follows: ++, strong staining; +, moderate staining; −, negative staining as described in [Table I](#t1-ijo-41-06-1985){ref-type="table"}. Photomicrographs show representative tissue staining patterns of each group. (A--C) E-cadherin; (D--F) Vimentin; (A and D) (−); (B and E) (+); (C and F) (++). Bar, 50 *μ*m.](IJO-41-06-1985-g02){#f1-ijo-41-06-1985}

![Immunohistochemical analysis of Brachyury expression in SCC tissue. Staining intensity of Brachyury in SCC cells was classified as follows: ++, strong staining; +, moderate staining; and −, negative staining as described in [Table I](#t1-ijo-41-06-1985){ref-type="table"}. Pattern of cellular localization was scored as: Type I, negative staining; Type II, positive only in the cytoplasm; Type III, positive only in the nucleus; Type IV, positive in both the cytoplasm and nucleus. Photomicrographs show representative staining patterns of each group. (A) Negative (−); (B) Weak positive in the cytoplasm (+); (C) Strong positive in the cytoplasm (++); (D) Weak positive in the nucleus (+); (E) Strong positive in the nucleus (++); and (F) Strong positive in the cytoplasm and nucleus (++). Bar, 50 *μ*m.](IJO-41-06-1985-g03){#f2-ijo-41-06-1985}

![Triple immunofluorescence staining analysis of Brachyury, E-cadherin, and Vimentin expression in SCC tissue. Each protein was visualized by secondary antibodies: Brachyury, green; E-cadherin, blue; and Vimentin, red. (A--D) Representative staining of EMT-negative, Brachyury-negative SCC. (E--H) Representative staining of EMT-positive, Brachyury-positive SCC. (A and E) Brachyury; (B and F) E-cadherin; (C and G) Vimentin; and (D and H) Merged image. Bar, 50 *μ*m.](IJO-41-06-1985-g04){#f3-ijo-41-06-1985}

![Kaplan-Meier survival analysis. Survival rate was estimated with the Kaplan-Meier method and analyzed using the log-rank test. Overall (A) and disease-free (B) survival of patients with tumors of the indicated status for (a) Brachyury, (b) E-cadherin, and (c) Vimentin are shown. ^\*^χ^2^ statistics.](IJO-41-06-1985-g00){#f4-ijo-41-06-1985}

![Kaplan-Meier survival analysis for EMT pattern and Brachyury expression. Survival rate was estimated with the Kaplan-Meier method and analyzed using the log-rank test. Overall (A) and disease-free (B) survival of patients with tumors of the indicated status for (a) EMT and (b) Brachyury with EMT are shown. ^\*^χ^2^ statistics.](IJO-41-06-1985-g01){#f5-ijo-41-06-1985}

###### 

Classification of staining density.

                                                      −        \+           ++       Unit
  --------------------------------------- ----------- -------- ------------ -------- -------------
  Brachyury                               Nuclear     \<0.2    0.2--0.7     \>0.7    
  Control: lymphocyte                     Cytoplasm   \<0.1    0.1--0.25    \>0.25   Ratio
  E-cadherin                                          \<0.37   0.37--0.54   \>0.54   
  Control: normal epithelium                                                         
  Vimentin                                            0        0--10        \>10     Cells/field
  No. of positive cells in a ×400 field                                              

$$\text{Expression}\,\text{strength} = \frac{(\text{mean}\,\text{density}\,\text{of}\,\text{positive}\,\text{signal}\,)\, - \,(\text{mean}\,\text{density}\,\text{of}\,\text{background}\,\text{staining})}{(\text{mean}\,\text{density}\,\text{of}\,\text{positive}\,\text{control})\, - \,(\text{mean}\,\text{density}\,\text{of}\,\text{back}\,\text{ground}\,\text{staining})}$$

###### 

Relation between EMT and clinicopathological factors.

                           Cases   E-cadherin   Vimentin   EMT                                             
  ------------------------ ------- ------------ ---------- ----- ------- ----- ---- ---- ------- ----- --- -------
  Age                                                                                                      
    ≤65                    88      30           28         30    NS      76    8    4    NS      83    5   NS
    \>65                   64      18           28         18            48    9    7            57    7   
  Sex                                                                                                      
    Male                   97      29           33         35    NS      78    12   7    NS      90    7   NS
    Female                 55      19           23         13            46    5    4            50    5   
  Clinical stage                                                                                           
    T1                     37      13           13         11    NS      33    3    1    NS      36    1   NS
    T2                     62      17           25         20            50    8    4            58    4   
    T3                     29      12           9          8             25    3    1            25    4   
    T4                     24      6            9          9             16    3    5            21    3   
  Tumor site                                                                                               
    Buccal mucosa          14      7            5          2     NS      10    3    1    0.021   13    1   NS
    Upper gingiva          7       2            4          1             3     1    3            5     2   
    Lower gingiva          39      10           13         16            34    3    2            36    3   
    Tongue                 81      27           26         28            67    10   4            75    6   
    Oral floor             11      2            8          1             10    0    1            11    0   
  Lymph node involvement                                                                                   
    Positive               56      24           15         17    0.049   39    9    8    0.009   47    9   0.009
    Negative               96      24           41         31            85    8    3            93    3   
  Distant metastases                                                                                       
    Positive               13      10           0          3     0.001   7     2    4    0.002   8     5   0.001
    Negative               139     38           56         45            117   15   7            132   7   
  Tumor differentiation                                                                                    
    Well                   132     37           50         45    0.041   107   15   10   NS      123   9   NS
    Moderate               19      11           6          2             16    2    1            16    3   
    Poor                   1       0            0          1             1     0    0            1     0   
  Pattern of invasion                                                                                      
    1                      2       1            1          0     NS      2     0    0    0.030   2     0   NS
    2                      37      10           14         13            32    3    2            35    2   
    3                      82      23           31         28            69    5    8            77    5   
    4                      31      14           10         7             21    9    1            26    5   

χ^2^ test: NS, not significant. p\<0.05.

###### 

Relation between expression pattern of Brachyury and clinicopathological factors.

                           Cases   Nuclear   Cytoplasm   Expression pattern                                                        
  ------------------------ ------- --------- ----------- -------------------- --------- ---- ---- ---- ------- ---- ---- ---- ---- -------
  Age                                                                                                                              
    ≤65                    88      34        23          31                   NS        55   16   17   NS      29   5    26   28   0.039
    \>65                   64      28        20          16                             30   15   19           15   13   15   21   
  Sex                                                                                                                              
    Male                   97      36        25          36                   NS        47   22   28   0.041   22   14   25   36   NS
    Female                 55      26        18          11                             38   9    8            22   4    16   13   
  Clinical stage                                                                                                                   
    T1                     37      27        2           8                    \<0.001   24   4    9    NS      21   6    3    7    0.001
    T2                     62      25        23          14                             35   11   16           16   9    19   18   
    T3                     29      5         11          13                             15   6    8            4    1    11   13   
    T4                     24      5         7           12                             11   10   3            3    2    8    11   
  Tumor site                                                                                                                       
    Buccal mucosa          14      6         5           3                    NS        9    1    4    NS      4    2    5    3    NS
    Upper gingiva          7       4         2           1                              2    3    2            2    2    0    3    
    Lower gingiva          39      11        13          15                             20   11   8            6    5    14   14   
    Tongue                 81      36        22          23                             47   13   21           28   8    19   26   
    Oral floor             11      5         1           5                              7    3    1            4    1    3    3    
  Lymph node involvement                                                                                                           
    Positive               56      13        22          21                   0.003     26   10   20   0.028   7    6    19   24   0.004
    Negative               96      49        21          26                             59   21   16           37   12   22   25   
  Distant metastases                                                                                                               
    Positive               13      4         3           6                    NS        5    2    6    NS      2    2    3    6    NS
    Negative               139     58        40          41                             80   29   30           42   16   38   43   
  Tumor differentiation                                                                                                            
    Well                   132     58        37          37                   0.043     74   27   31   NS      43   16   31   42   0.030
    Moderate               19      3         6           10                             10   4    5            0    2    10   7    
    Poor                   1       1         0           0                              1    0    0            1    0    0    0    
  Pattern of invasion                                                                                                              
    1                      2       1         0           1                    0.024     2    0    0    0.022   1    0    1    0    0.006
    2                      37      21        8           8                              20   9    8            14   7    6    10   
    3                      82      35        25          22                             54   13   15           28   7    26   21   
    4                      31      5         10          16                             9    9    13           1    4    8    18   

χ^2^ test: NS, not significant. Significant, p\<0.05.

###### 

Relationships among Brachyury expression, EMT markers, and EMT.

  Brachyury expression pattern   E-cadherin   Vimentin   EMT                                       
  ------------------------------ ------------ ---------- ----- ---- ---- ---- --- ------- ---- --- -------
  I                              14           16         14    NS   42   1    1   0.002   43   1   0.035
  II                             4            8          6          11   4    3           16   2   
  III                            15           18         8          38   2    1           40   1   
  IV                             15           14         20         33   10   6           41   8   

χ^2^ test: NS, not significant. p\<0.05.

###### 

Logistic regression analysis of predictive factors.

                              Univariate analysis   Multivariate analysis                                   
  --------------------------- --------------------- ----------------------- --------------- ------- ------- ---------------
  Lymph node involvement                                                                                    
    Brachyury                                                                                               
      Negative vs. positive   4.39                  0.001                   1.799--10.714   3.952   0.040   1.563--9.988
    E-cadherin                                                                                              
      Negative vs. positive   0.444                 0.024                   0.220--0.897    0.478   0.089   0.204--1.120
    Vimentin                                                                                                
      Negative vs. positive   3.368                 0.005                   1.443--7.864    2.020   0.215   0.665--6.131
    EMT                                                                                                     
      Negative vs. positive   5.936                 0.010                   1.534--22.965   1.533   0.653   0.238--9.890
  Distant metastases                                                                                        
    Brachyury                                                                                               
      Negative vs. positive   2.381                 0.272                   0.506--11.215   1.836   0.475   0.347--9.713
    E-cadherin                                                                                              
      Negative vs. positive   0.113                 0.001                   0.029--0.432    0.141   0.023   0.026--0.766
    Vimentin                                                                                                
      Negative vs. positive   4.558                 0.012                   1.398--14.860   2.506   0.468   0.210--29.969
    EMT                                                                                                     
      Negative vs. positive   11.786                \<0.001                 3.051--45.527   1.533   0.771   0.086--27.307

[^1]: Contributed equally
